Study to evaluate the immunogenicity, reactogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) liquid vaccine, when given to healthy infants, in Philippines - Trial 2015-001544-11
Access comprehensive clinical trial information for 2015-001544-11 through Pure Global AI's free database. This phase not specified trial is sponsored by GlaxoSmithKline Biologicals and is currently status unknown. The study focuses on Healthy volunteers.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Free Database
Powered by Pure Global AI
840K+ Trials
2015-001544-11
Trial Details
EU Clinical Trials Register • 2015-001544-11
Study to evaluate the immunogenicity, reactogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) liquid vaccine, when given to healthy infants, in Philippines
Study Focus
Sponsor & Location
GlaxoSmithKline Biologicals
Timeline & Enrollment
N/A
N/A
N/A
Primary Outcome
Anti-RV IgA antibody seroconversion, when administered concomitantly with the second and third routine EPI immunization
ICD-10 Classifications
Healthy person accompanying sick person
Routine general health check-up of armed forces
Routine general health check-up of sports teams
Routine general health check-up of inhabitants of institutions
Data Source
EU Clinical Trials Register
2015-001544-11
Non-Device Trial